Immune cell migration as a means to control immune privilege: Lessons from the CNS and tumors

Immunological Reviews

Volumn 213, Issue 1, 2006, Pages 195-212

  Mrass, Paulus ^a   Weninger, Wolfgang ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adhesion molecules; Chemokines; Leukocyte trafficking; T cells; Two photon microscopy

Indexed keywords

ALPHA4 INTEGRIN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL ADHESION; CELL MIGRATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHOROID PLEXUS; DENDRITIC CELL; ENDOTHELIUM; EXTRAVASCULAR SPACE; HUMAN; HYPOTHESIS; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INTERSTITIUM; LEUKOCYTE MIGRATION; LYMPHOCYTE MIGRATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MENINX; MICROGLIA; MICROSCOPY; MOLECULAR DYNAMICS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; STEADY STATE; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; NEOPLASMS;

EID: 33748750976     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00433.x     Document Type: Review

References (186)

1. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1-54.
2. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-889.
3. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62:593-604.
4. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28.
5. Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. Bioessays 1993;15:341-346.
6. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 1994;15:218-224.
7. Agrawal S, et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006;203:1007-1019.
8. Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 1999;11:125-137.
9. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001;36:118-124.
10. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005;26:485-495.
11. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569-581.
12. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004;61:1613-1615.
13. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005;204:208-231.
14. Kieseier BC, Hemmer B, Hartung HP. Multiple sclerosis-novel insights and new therapeutic strategies. Curr Opin Neurol 2005;18:211-220.
15. Williams RM, Zipfel WR, Webb WW. Multiphoton microscopy in biological research. Curr Opin Chem Biol 2001;5:603-608.
16. Cahalan MD, Parker I, Wei SH, Miller MJ. Two-photon tissue imaging: seeing the immune system in a fresh light. Nat Rev Immunol 2002;2:872-880.
17. Sumen C, Mempel TR, Mazo IB, von Andrian UH. Intravital microscopy: visualizing immunity in context. Immunity 2004;21:315-329.
18. Bousso P, Robey EA. Dynamic behavior of T cells and thymocytes in lymphoid organs as revealed by two-photon microscopy. Immunity 2004;21:349-355.
19. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
20. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
21. Iparraguirre A, Weninger W. Visualizing T cell migration in vivo. Int Arch Allergy Immunol 2003;132:277-293.
22. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1034.
23. Weninger W, von Andrian UH. Chemokine regulation of naive T cell traffic in health and disease. Semin Immunol 2003;15:257-270.
24. Weninger W, et al. Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol 2003;170:4638-4648.
25. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005;11:335-339.
26. Mora JR, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003;424:88-93.
27. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002;195:135-141.
28. Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235-243.
29. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211-222.
30. Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res 2005;31:57-74.
31. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
32. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 2001;194:953-966.
33. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
34. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006;24:209-226.
35. Huehn J, Hamann A. Homing to suppress: address codes for Treg migration. Trends Immunol 2005;26:632-636.
36. Huehn J, Siegmund K, Hamann A. Migration rules: functional properties of naive and effector/memory-like regulatory T cell subsets. Curr Top Microbiol Immunol 2005;293:89-114.
37. Chen Q, Wang WC, Evans SS. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 2003;52:670-679.
38. Denk W, Strickler JH, Webb WW. Two-photon laser scanning fluorescence microscopy. Science 1990;248:73-76.
39. Germain RN, et al. An extended vision for dynamic high-resolution intravital immune imaging. Semin Immunol 2005;17:431-441.
40. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002;296:1869-1873.
41. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003;4:579-585.
42. Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci USA 2004;101:998-1003.
43. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-159.
44. Lindquist RL, et al. Visualizing dendritic cell networks in vivo. Nat Immunol 2004;5:1243-1250.
45. Rosenbaum JT, Planck SR, Martin TM, Crane I, Xu H, Forrester JV. Imaging ocular immune responses by intravital microscopy. Int Rev Immunol 2002;21:255-272.
46. Becher B, Prat A, Antel JP. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000;29:293-304.
47. Brabb T, von Dassow P, Ordonez N, Schnabel B, Duke B, Goverman J. In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J Exp Med 2000;192:871-880.
48. Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001;2:917-924.
49. Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004;44:65-81.
50. Carson MJ, Sutcliffe JG. Balancing function vs. self defense: the CNS as an active regulator of immune responses. J Neurosci Res 1999;55:1-8.
51. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
52. Aloisi F. Immune function of microglia. Glia 2001;36:165-179.
53. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002;40:133-139.
54. Hauwel M, Furon E, Canova C, Griffiths M, Neal J, Gasque P. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, "protective" glial stem cells and stromal ependymal cells. Brain Res Brain Res Rev 2005;48:220-233.
55. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 1996;74:599-608.
56. Bechmann I, et al. Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci 2001;14:1651-1658.
57. Greter M, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334.
58. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999;58:233-247.
59. Karman J, Ling C, Sandor M, Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 2004;173:2353-2361.
60. Juedes AE, Ruddle NH. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol 2001;166:5168-5175.
61. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001;166:2717-2726.
62. Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001;36:156-164.
63. Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD, Owens T. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 1998;161:3767-3775.
64. Heppner FL, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005;11:146-152.
65. Kalla R, et al. Microglia and the early phase of immune surveillance in the axotomized facial motor nucleus: impaired microglial activation and lymphocyte recruitment but no effect on neuronal survival or axonal regeneration in macrophage-colony stimulating factor-deficient mice. J Comp Neurol 2001;436:182-201.
66. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-1318.
67. Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752-758.
68. Raivich G. Like cops on the beat: the active role of resting microglia. Trends Neurosci 2005;28:571-573.
69. Hickey WF, Vass K, Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol 1992;51:246-256.
70. McMenamin PG. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol 1999;405:553-562.
71. McMenamin PG, Wealthall RJ, Deverall M, Cooper SJ, Griffin B. Macrophages and dendritic cells in the rat meninges and choroid plexus: three-dimensional localisation by environmental scanning electron microscopy and confocal microscopy. Cell Tissue Res 2003;313:259-269.
72. Hatterer E, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 2006;107:806-812.
73. Polfliet MM, et al. Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. J Immunol 2001;167:4644-4650.
74. Goverman J, Brabb T, Paez A, Harrington C, von Dassow P. Initiation and regulation of CNS autoimmunity. Crit Rev Immunol 1997;17:469-480.
75. Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech 2001;52:112-129.
76. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin LM. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol 2001;153:933-946.
77. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005;26:565-571.
78. Rubin SA, Yednock TA, Carbone KM. In vivo treatment with anti-alpha4 integrin suppresses clinical and pathological evidence of Borna disease virus infection. J Neuroimmunol 1998;84:158-163.
79. Roffe E, Silva AA, Marino AP, dos Santos PV, Lannes-Vieira J. Essential role of VLA-4/VCAM-1 pathway in the establishment of CD8+ T-cell-mediated Trypanosoma cruzi-elicited meningoencephalitis. J Neuroimmunol 2003;142:17-30.
80. Smith JP, Morris-Downes M, Brennan FR, Wallace GJ, Amor S. A role for alpha4-integrin in the pathology following Semliki Forest virus infection. J Neuroimmunol 2000;106:60-68.
81. Kivisakk P, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA 2003;100:8389-8394.
82. Giunti D, et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol 2003;73:584-590.
83. Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000;123:1092-1101.
84. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28:254-260.
85. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 2006;113:477-485.
86. Weninger W, et al. Specialized contributions by alpha(1, 3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal microvessels. Immunity 2000;12:665-676.
87. Carvalho-Tavares J, Hickey MJ, Hutchison J, Michaud J, Sutcliffe IT, Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000;87:1141-1148.
88. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66.
89. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
90. Kent SJ, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
91. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 1999;96:6896-6901.
92. Dopp JM, Breneman SM, Olschowka JA. Expression of ICAM-1, VCAM-1, L-selectin, and leukosialin in the mouse central nervous system during the induction and remission stages of experimental allergic encephalomyelitis. J Neuroimmunol 1994;54:129-144.
93. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, Hoch G. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 1998;102:2096-2105.
94. Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990;60:53-61.
95. Laschinger M, Engelhardt B. Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol 2000;102:32-43.
96. Kerfoot SM, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 2002;169:1000-1006.
97. Battistini L, et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003;101:4775-4782.
98. Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 2001;108:557-565.
99. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 1993;268:24655-24664.
100. Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 1998;111:1165-1174.
101. Gonzalez-Amaro R, Mittelbrunn M, Sanchez-Madrid F. Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? Immunology 2005;116:289-296.
102. Rice GP, Hartung HP, Calabresi PA. Antialpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-1342.
103. Miller DH, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
104. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
105. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
106. Van Assche G, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
107. Gallia GL, Houff SA, Major EO, Khalili K. Review: JC virus infection of lymphocytes-revisited. J Infect Dis 1997;176:1603-1609.
108. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72.
109. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005;8:1275.
110. Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
111. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
112. Rudick RA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
113. Piccio L, et al. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 2002;168:1940-1949.
114. Piccio L, et al. Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. J Immunol 2005;174:5805-5813.
115. Engelhardt B, Vestweber D, Hallmann R, Schulz M. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 1997;90:4459-4472.
116. Osmers I, Bullard DC, Barnum SR. PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;166:193-196.
117. Engelhardt B, et al. P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J Immunol 2005;175:1267-1275.
118. McCarron RM, Wang L, Racke MK, McFarlin DE, Spatz M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 1993;43:23-30.
119. Laschinger M, Vajkoczy P, Engelhardt B. Encephalitogenic T cells use LFA-1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo. Eur J Immunol 2002;32:3598-35606.
120. Cannella B, Cross AH, Raine CS. Antiadhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 1993;46:43-55.
121. Willenborg DO, Simmons RD, Tamatani T, Miyasaka M. ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J Neuroimmunol 1993;45:147-154.
122. Welsh CT, Rose JW, Hill KE, Townsend JJ. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J Neuroimmunol 1993;43:161-167.
123. Archelos JJ, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993;34:145-154.
124. Samoilova EB, Horton JL, Chen Y. Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1-deficient mice. Cell Immunol 1998;190:83-89.
125. Reiss Y, Hoch G, Deutsch U, Engelhardt B. T cell interaction with ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells. Eur J Immunol 1998;28:3086-3099.
126. Xie C, et al. Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J Exp Med 2006;203:985-994.
127. Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003;161:839-843.
128. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-675.
129. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005;6:1182-1190.
130. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. NEngl JMed 2006;354:610-621.
131. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-411.
132. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:167-176.
133. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 1996;19:331-338.
134. Sorensen TL, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-815.
135. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006;27:48-55.
136. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 2005;48:16-42.
137. Alt C, Laschinger M, Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 2002;32:2133-2144.
138. Harkness KA, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. J Neuroimmunol 2003;142:1-9.
139. Shukaliak JA, Dorovini-Zis K. Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 2000;59:339-352.
140. Omari KM, Chui R, Dorovini-Zis K. Induction of beta-chemokine secretion by human brain microvessel endothelial cells via CD40/CD40L interactions. J Neuroimmunol 2004;146:203-208.
141. Quandt J, Dorovini-Zis K. The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J Neuropathol Exp Neurol 2004;63:350-362.
142. Weiss JM, Downie SA, Lyman WD, Berman JW. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J Immunol 1998;161:6896-6903.
143. dos Santos AC, Barsante MM, Esteves Arantes RM, Bernard CC, Teixeira MM, Carvalho-Tavares J. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis - an intravital microscopy study. J Neuroimmunol 2005;162:122-129.
144. Shrikant P, Chung IY, Ballestas ME, Benveniste EN. Regulation of intercellular adhesion molecule-1 gene expression by tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma in astrocytes. J Neuroimmunol 1994;51:209-220.
145. Frohman EM, et al. The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J Neuroimmunol 1989;23:117-124.
146. Ambrosini E, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005;64:706-715.
147. Ransohoff RM, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993;7:592-600.
148. Liu MT, et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 2000;165:2327-2330.
149. Klein RS, et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005;79:11457-11466.
150. Kawakami N, Nagerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flugel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J Exp Med 2005;201:1805-1814.
151. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
152. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
153. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
154. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-675.
155. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-205.
156. Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
157. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
158. Yu P, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-791.
159. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006;86:231-245.
160. Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005;67:35-50.
161. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133.
162. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003;63:8384-8392.
163. Casares N, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171:5931-5939.
164. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002;32:3267-3275.
165. Jones E, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
166. Wang HY, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-118.
167. Woo EY, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
168. Woo EY, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772.
169. Liyanage UK, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
170. Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992;52:4265-4268.
171. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, Jain RK. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995;55:4824-4829.
172. Dirkx AE, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003;63:2322-2329.
173. Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999;59:5245-5249.
174. Skitzki J, et al. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 2004;64:2183-2191.
175. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-111.
176. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693.
177. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003;8:396-403.
178. Nooijen PT, et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998;152:679-682.
179. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995;181:811-816.
180. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996;56:1111-1117.
181. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996;88:667-673.
182. Tromp SC, et al. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 2000;12:671-676.
183. Bessa X, et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 2002;122:1122-1132.
184. Borgstrom P, Hughes GK, Hansell P, Wolitsky BA, Sriramarao P. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. J Clin Invest 1997;99:2246-2253.
185. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
186. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003;24:327-334.